Synergistic effect of celecoxib in tumor necrosis factor-related apoptosis-inducing ligand treatment in osteosarcoma cells
Authors:
Open Access
- 22 July 2014
- journal article
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 10 (4) , 2198-2202
Abstract
Tumor necrosis factor-related apoptosis‑inducing ligand (TRAIL) is under clinical development as a cancer therapeutic as it has been shown to induce apoptosis in numerous types of cancer cells without significant toxicity towards normal cells. However, the majority of osteosarcoma (OS) tumors are resistant to TRAIL. Thus, the development of cancer therapeutics that overcome TRAIL resistance is required. In the present study, celecoxib (CXB), a non-steroidal anti‑inflammatory drug, was administered in combination with TRAIL to induce cell apoptosis and the doses of the two drugs were simultaneously reduced. The effects of this combination treatment were examined in MG-63 human OS cancer cell lines in culture. Assays of proliferation, apoptosis and tumor growth were performed, along with analysis of the proteins involved. The results revealed that CXB sensitized TRAIL-resistant MG-63 OS cells to TRAIL‑induced apoptosis through downregulation of cellular B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein, caspase-8 and caspase-3. Furthermore, combination treatment reduced tumor growth in a nude rat model. In conclusion, the experimental results provided evidence that the combined administration of CXB and TRAIL is potentially a novel treatment method of OS tumors.Keywords
This publication has 26 references indexed in Scilit:
- Effect of ABCB1 and ABCC3 Polymorphisms on Osteosarcoma Survival after Chemotherapy: A Pharmacogenetic StudyPLOS ONE, 2011
- Osteosarcoma treatment: state of the artCancer and Metastasis Reviews, 2009
- Neoadjuvant Chemotherapy for Osteosarcoma of the Extremities in Preadolescent PatientsJournal of Pediatric Hematology/Oncology, 2008
- The TRAIL apoptotic pathway in cancer onset, progression and therapyNature Reviews Cancer, 2008
- Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)Journal of Clinical Oncology, 2008
- TRAIL in cancer therapy: present and future challengesExpert Opinion on Therapeutic Targets, 2007
- Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAILExperimental Cell Research, 2007
- Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugsCell Death & Differentiation, 2004
- Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapyCytokine & Growth Factor Reviews, 2003
- Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivoNature Medicine, 1999